环孢素A联合方案治疗低危骨髓增生异常综合征

目的探讨环孢素A（CsA）联合造血生长因子治疗低危骨髓增生异常综合征（MDS）的临床疗效。方法用CsA联合造血生长因子治疗低危骨髓增生异常综合征患者30例,定期观察患者外周血象和骨髓象变化,并随诊观察远期疗效。结果30例患者治疗总有效率为80.0%（24/30）。70.0%（21/30）患者血液学指标改善并摆脱输血依赖,全部患者无严重毒副反应出现。结论CsA联合造血生长因子治疗低危骨髓增生异常综合征疗效可靠,耐受性好。

Clinical Effect of Cyclosporin a Combined with Hematopoietic Growth Factor for Low-risk Myelodysplastic Syndrome

Objective To explore the clinical result of cyclosporin A（CsA） combined with hematopoietic growth factor in the treatment of low-risk myelodysplastic syndrome（MDS）. Methods 30 cases with low-risk MDS were treated with CsA and hematopoietic growth factor. The changes of peripheral blood cells and bone marrow were observed regularly. A follow-up observation for long-term therapy effect was carried out. Results The total effective rate of 30 patients was 80. 0% （24/30）. No serious sideeffects occurred in all treated patients. The anemia in 70.0% （21/30） patients was improved and these transfusion-dependent patients achieved transfusion independence. Conclusions The treatment of low-risk MDS by CsA combined with hematopoietic growth factor is safe and effective.